117 related articles for article (PubMed ID: 21062644)
1. A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease.
Mievis S; Blum D; Ledent C
Neurobiol Dis; 2011 Feb; 41(2):570-6. PubMed ID: 21062644
[TBL] [Abstract][Full Text] [Related]
2. Worsening of Huntington disease phenotype in CB1 receptor knockout mice.
Mievis S; Blum D; Ledent C
Neurobiol Dis; 2011 Jun; 42(3):524-9. PubMed ID: 21406230
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models.
Li W; Silva HB; Real J; Wang YM; Rial D; Li P; Payen MP; Zhou Y; Muller CE; Tomé AR; Cunha RA; Chen JF
Neurobiol Dis; 2015 Jul; 79():70-80. PubMed ID: 25892655
[TBL] [Abstract][Full Text] [Related]
4. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
[TBL] [Abstract][Full Text] [Related]
5. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
[TBL] [Abstract][Full Text] [Related]
6. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
[TBL] [Abstract][Full Text] [Related]
7. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease.
Canals JM; Pineda JR; Torres-Peraza JF; Bosch M; Martín-Ibañez R; Muñoz MT; Mengod G; Ernfors P; Alberch J
J Neurosci; 2004 Sep; 24(35):7727-39. PubMed ID: 15342740
[TBL] [Abstract][Full Text] [Related]
8. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.
Charvin D; Vanhoutte P; Pagès C; Borrelli E; Caboche J
Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12218-23. PubMed ID: 16103364
[TBL] [Abstract][Full Text] [Related]
9. Modulation of nucleosome dynamics in Huntington's disease.
Stack EC; Del Signore SJ; Luthi-Carter R; Soh BY; Goldstein DR; Matson S; Goodrich S; Markey AL; Cormier K; Hagerty SW; Smith K; Ryu H; Ferrante RJ
Hum Mol Genet; 2007 May; 16(10):1164-75. PubMed ID: 17403718
[TBL] [Abstract][Full Text] [Related]
10. Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction.
Smith R; Petersén A; Bates GP; Brundin P; Li JY
Neurobiol Dis; 2005 Dec; 20(3):673-84. PubMed ID: 15967669
[TBL] [Abstract][Full Text] [Related]
11. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.
Cyr M; Sotnikova TD; Gainetdinov RR; Caron MG
FASEB J; 2006 Dec; 20(14):2541-3. PubMed ID: 17065224
[TBL] [Abstract][Full Text] [Related]
12. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease.
Petrasch-Parwez E; Nguyen HP; Löbbecke-Schumacher M; Habbes HW; Wieczorek S; Riess O; Andres KH; Dermietzel R; Von Hörsten S
J Comp Neurol; 2007 Apr; 501(5):716-30. PubMed ID: 17299753
[TBL] [Abstract][Full Text] [Related]
13. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
[TBL] [Abstract][Full Text] [Related]
14. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
[TBL] [Abstract][Full Text] [Related]
15. Remodeling of striatal NMDA receptors by chronic A(2A) receptor blockade in Huntington's disease mice.
Martire A; Ferrante A; Potenza RL; Armida M; Ferretti R; Pézzola A; Domenici MR; Popoli P
Neurobiol Dis; 2010 Jan; 37(1):99-105. PubMed ID: 19804830
[TBL] [Abstract][Full Text] [Related]
16. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease.
Saydoff JA; Garcia RA; Browne SE; Liu L; Sheng J; Brenneman D; Hu Z; Cardin S; Gonzalez A; von Borstel RW; Gregorio J; Burr H; Beal MF
Neurobiol Dis; 2006 Dec; 24(3):455-65. PubMed ID: 17011205
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.
Ebert AD; Barber AE; Heins BM; Svendsen CN
Exp Neurol; 2010 Jul; 224(1):155-62. PubMed ID: 20227407
[TBL] [Abstract][Full Text] [Related]
18. Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease.
Popoli P; Blum D; Martire A; Ledent C; Ceruti S; Abbracchio MP
Prog Neurobiol; 2007 Apr; 81(5-6):331-48. PubMed ID: 17303312
[TBL] [Abstract][Full Text] [Related]
19. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.
Southwell AL; Ko J; Patterson PH
J Neurosci; 2009 Oct; 29(43):13589-602. PubMed ID: 19864571
[TBL] [Abstract][Full Text] [Related]
20. Elucidating the role of the A2A adenosine receptor in neurodegeneration using neurons derived from Huntington's disease iPSCs.
Chiu FL; Lin JT; Chuang CY; Chien T; Chen CM; Chen KH; Hsiao HY; Lin YS; Chern Y; Kuo HC
Hum Mol Genet; 2015 Nov; 24(21):6066-79. PubMed ID: 26264576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
